| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1317856 | Journal of Inorganic Biochemistry | 2012 | 10 Pages |
The study of metal complexes for the treatment of cancer diseases has resulted in the identification of some unique properties of ruthenium-based compounds. Among these inorganic-based agents, two of them, namely the ruthenium(III) drugs NAMI-A and KP1019 have undertaken with some success the clinical evaluations of phase I and preliminary phase II trials in patients. Here we highlight the strategies that have led to the discovery of metal-based (NAMI-A and KP1019) and of organometallic (RM175, RAPTA-T, RDC11 and DW1/2) ruthenium-based complexes, and we report their main biological/pharmacological characteristics and expectations for further development.
Graphical abstractThe war of ruthenium-based drugs against cancer: those on the front line and the incoming reinforces.Figure optionsDownload full-size imageDownload as PowerPoint slide
